Closing of the second stage of the binding agreement of investment in and acquisition in stages of IOPtima

Tel Aviv (September 27, 2018) – Further to BioLight’s announcement dated November 21, 2017, regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima Ltd. (“IOPtima”or the “Company”) (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (the “Acquirer”), …

Continue reading

Agreement for the Examination of Cooperation with Wize Pharma; Immaterial Relations with an independent Director

Tel Aviv (June 12, 2018) – On June 11, 2018, Diagnostear Ltd. (“Diagnostear“)[1] entered into an agreement (the “Agreement”) with Wize Pharma Ltd. (“Wize Pharma” and together with Diagnostear  the “Parties“) to examine cooperation between the Parties for the development of a companion diagnostic tool of responders and …

Continue reading

Rights Offering Results

Tel Aviv (May 10, 2018) – BioLight Life Sciences Ltd. is pleased to announce the
completion and results of its Rights Offering. The Rights Offering record date was April 26,
2018, and the offer has ended and expired on May 9, 2018.
The Rights Offering entitled rights …

Continue reading